ES2431301T3 - Procedimiento para el diagnóstico precoz de carcinomas del cuello uterino - Google Patents
Procedimiento para el diagnóstico precoz de carcinomas del cuello uterino Download PDFInfo
- Publication number
- ES2431301T3 ES2431301T3 ES10765749T ES10765749T ES2431301T3 ES 2431301 T3 ES2431301 T3 ES 2431301T3 ES 10765749 T ES10765749 T ES 10765749T ES 10765749 T ES10765749 T ES 10765749T ES 2431301 T3 ES2431301 T3 ES 2431301T3
- Authority
- ES
- Spain
- Prior art keywords
- primers
- methylation
- dna
- znf671
- astn1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 61
- 210000003679 cervix uteri Anatomy 0.000 title claims description 6
- 201000009030 Carcinoma Diseases 0.000 title description 12
- 238000013399 early diagnosis Methods 0.000 title description 4
- 230000011987 methylation Effects 0.000 claims abstract description 75
- 238000007069 methylation reaction Methods 0.000 claims abstract description 75
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 57
- 238000001514 detection method Methods 0.000 claims abstract description 34
- 101000936741 Homo sapiens Astrotactin-1 Proteins 0.000 claims abstract description 29
- 102100027708 Astrotactin-1 Human genes 0.000 claims abstract description 28
- 101000915607 Homo sapiens Zinc finger protein 671 Proteins 0.000 claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
- 201000011510 cancer Diseases 0.000 claims abstract description 23
- 102100028943 Zinc finger protein 671 Human genes 0.000 claims abstract description 19
- 239000002243 precursor Substances 0.000 claims abstract description 19
- 101710120624 Astrotactin-1 Proteins 0.000 claims abstract description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 6
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 6
- 101710185494 Zinc finger protein Proteins 0.000 claims abstract description 5
- 102100023597 Zinc finger protein 816 Human genes 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 54
- 239000000523 sample Substances 0.000 claims description 47
- 230000008569 process Effects 0.000 claims description 12
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 8
- 102000040945 Transcription factor Human genes 0.000 claims description 7
- 108091023040 Transcription factor Proteins 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- 230000004544 DNA amplification Effects 0.000 claims description 2
- 238000007399 DNA isolation Methods 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 4
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 claims 3
- 238000013518 transcription Methods 0.000 abstract description 3
- 230000035897 transcription Effects 0.000 abstract description 3
- 239000013615 primer Substances 0.000 description 42
- 208000019065 cervical carcinoma Diseases 0.000 description 21
- 101150005988 cin2 gene Proteins 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 102100032449 EGF-like repeat and discoidin I-like domain-containing protein 3 Human genes 0.000 description 13
- 101001016381 Homo sapiens EGF-like repeat and discoidin I-like domain-containing protein 3 Proteins 0.000 description 13
- 101000864690 Homo sapiens Homeobox protein DLX-1 Proteins 0.000 description 13
- 102100030087 Homeobox protein DLX-1 Human genes 0.000 description 12
- 101150070189 CIN3 gene Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 9
- 239000007850 fluorescent dye Substances 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000007067 DNA methylation Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 108091029523 CpG island Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 238000009595 pap smear Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010058314 Dysplasia Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000103 Relaxin Proteins 0.000 description 3
- 102000003743 Relaxin Human genes 0.000 description 3
- 241000239226 Scorpiones Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000006607 hypermethylation Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100022105 Relaxin-3 receptor 1 Human genes 0.000 description 2
- 101710117864 Relaxin-3 receptor 1 Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 101150061050 CIN1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 102100032141 Cell death activator CIDE-A Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010049959 Discoidins Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 101000775570 Homo sapiens Cell death activator CIDE-A Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100034944 Relaxin-3 Human genes 0.000 description 1
- 101710113452 Relaxin-3 Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 101710180773 Zinc finger protein 671 Proteins 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004745 cervical carcinogenesis Effects 0.000 description 1
- 208000015698 cervical squamous intraepithelial neoplasia Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09011941 | 2009-09-18 | ||
| EP09011941A EP2308998A1 (de) | 2009-09-18 | 2009-09-18 | Verfahren zur frühen Diagnose von Karzinomen des Anogenitaltraktes |
| PCT/EP2010/005735 WO2011032721A1 (de) | 2009-09-18 | 2010-09-17 | Verfahren zur frühen diagnose von karzinomen des anogenitaltraktes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2431301T3 true ES2431301T3 (es) | 2013-11-25 |
Family
ID=41564137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10765749T Active ES2431301T3 (es) | 2009-09-18 | 2010-09-17 | Procedimiento para el diagnóstico precoz de carcinomas del cuello uterino |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8575326B2 (enExample) |
| EP (2) | EP2308998A1 (enExample) |
| JP (1) | JP5491631B2 (enExample) |
| CA (1) | CA2774458C (enExample) |
| DK (1) | DK2478117T3 (enExample) |
| ES (1) | ES2431301T3 (enExample) |
| WO (1) | WO2011032721A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102082098B1 (ko) * | 2012-05-11 | 2020-02-26 | 국립연구개발법인 고쿠리츠간켄큐센터 | 신장 세포암의 예후 예측방법 |
| CN104513851B (zh) * | 2013-10-08 | 2017-01-11 | 陈永恩 | 侦测膀胱癌的新颖表基因生物标记及其方法 |
| DE102015101555A1 (de) * | 2015-02-03 | 2016-08-04 | Oncgnostics GmbH BioInstrumentezentrum Jena | Verfahren und Kit zur Bestimmung des Risikos einer Entwicklung eines Zervixkarzinoms oder einer seiner malignen Vorstufen |
| US12331360B2 (en) * | 2017-09-29 | 2025-06-17 | Oncgnostics Gmbh | Risk determination for neoplasia and cancer |
| CN107760788B (zh) * | 2017-12-05 | 2021-03-02 | 武汉艾米森生命科技有限公司 | 一种检测宫颈细胞基因甲基化的核酸组合及试剂盒与应用 |
| US20220106644A1 (en) * | 2019-01-24 | 2022-04-07 | Mayo Foundation For Medical Education And Research | Detecting endometrial cancer |
| CN110452984A (zh) * | 2019-07-29 | 2019-11-15 | 韩林志 | 一种用于宫颈癌甲基化检测的甲基化基因组合、引物和探针组合、试剂盒及其使用方法 |
| CA3154354A1 (en) | 2019-10-31 | 2021-05-06 | William R. Taylor | Detecting ovarian cancer |
| WO2021133999A1 (en) * | 2019-12-23 | 2021-07-01 | Active Motif, Inc. | Methods and kits for the enrichment and detection of dna and rna modifications and functional motifs |
| CA3208505A1 (en) | 2021-02-26 | 2022-09-01 | Oncgnostics Gmbh | Diagnosis and risk determination for head and neck cancer |
| CN112941189B (zh) * | 2021-05-06 | 2023-07-21 | 中南大学 | 宫颈癌早筛分子标志物znf671基因甲基化检测的引物探针组合物及试剂盒和使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10019058A1 (de) * | 2000-04-06 | 2001-12-20 | Epigenomics Ag | Detektion von Variationen des DNA-Methylierungsprofils |
| US20070105105A1 (en) * | 2003-05-23 | 2007-05-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| AU2004256425A1 (en) * | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
-
2009
- 2009-09-18 EP EP09011941A patent/EP2308998A1/de not_active Withdrawn
-
2010
- 2010-09-17 ES ES10765749T patent/ES2431301T3/es active Active
- 2010-09-17 DK DK10765749.6T patent/DK2478117T3/da active
- 2010-09-17 US US13/496,812 patent/US8575326B2/en active Active
- 2010-09-17 EP EP10765749.6A patent/EP2478117B1/de active Active
- 2010-09-17 JP JP2012529163A patent/JP5491631B2/ja active Active
- 2010-09-17 CA CA2774458A patent/CA2774458C/en active Active
- 2010-09-17 WO PCT/EP2010/005735 patent/WO2011032721A1/de not_active Ceased
-
2013
- 2013-08-29 US US14/013,272 patent/US9228238B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2478117A1 (de) | 2012-07-25 |
| CA2774458C (en) | 2021-04-27 |
| JP2013505007A (ja) | 2013-02-14 |
| CA2774458A1 (en) | 2011-03-24 |
| US8575326B2 (en) | 2013-11-05 |
| EP2478117B1 (de) | 2013-07-31 |
| US20120208180A1 (en) | 2012-08-16 |
| JP5491631B2 (ja) | 2014-05-14 |
| WO2011032721A1 (de) | 2011-03-24 |
| EP2308998A1 (de) | 2011-04-13 |
| US9228238B2 (en) | 2016-01-05 |
| US20130344479A1 (en) | 2013-12-26 |
| DK2478117T3 (da) | 2013-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2431301T3 (es) | Procedimiento para el diagnóstico precoz de carcinomas del cuello uterino | |
| CN113755603B (zh) | 子宫内膜癌早期筛查诊断用标志物、引物探针及试剂盒 | |
| AU2020310247B2 (en) | Gene marker combination and use thereof | |
| ES2928068T3 (es) | Clasificador de metilación para detección de cánceres invasivos inducidos por HPV, cánceres ginecológicos y anogenitales no inducidos por HPV y sus lesiones precursoras de alto grado | |
| CN110564857B (zh) | 一种用于早期宫颈癌检测的组合物及试剂盒 | |
| WO2021004215A1 (zh) | 一种多基因联合检测试剂 | |
| CN110964809A (zh) | Hoxa7甲基化检测试剂 | |
| CN117265096A (zh) | 用于宫颈高级别病变和宫颈癌早期检测的试剂盒 | |
| CN113913522B (zh) | 子宫内膜癌检测的试剂及试剂盒 | |
| CN113621704B (zh) | 肝癌的检测和诊断的试剂及试剂盒 | |
| TWI385252B (zh) | 一種癌症篩檢的方法 | |
| WO2022179708A1 (en) | Diagnosis and risk determination for head and neck cancer | |
| WO2005049861A2 (en) | Method for the analysis of gynaecological cell proliferative disorders | |
| CN118600006A (zh) | 基因甲基化在宫颈癌和子宫内膜癌检测中的应用 | |
| US12116639B2 (en) | Markers, primers, probes and kit for early screening and diagnosis of endometrial cancer | |
| CN113403393A (zh) | 一种癌症和/或癌前病变检测试剂盒 | |
| CN118685528B (zh) | 一种宫颈癌基因甲基化检测的生物标记物、引物探针组合及其应用 | |
| CN115851959B (zh) | 一种用于食管鳞状细胞癌及癌前病变的诊断或辅助诊断的试剂及检测试剂盒 | |
| AU2023408532A1 (en) | Methylation marker for cancer | |
| WO2024001602A1 (zh) | 一种用于检测胃癌的组合物，试剂盒及其用途 | |
| CN115961048A (zh) | 一种基因甲基化检测引物组合、试剂及其应用 | |
| CN118581218A (zh) | 用于hpv阴性宫颈癌检测的核酸产品、试剂盒及应用 | |
| CN118879869A (zh) | 一种用于原发性肝细胞癌检测的分子标记物及其应用 | |
| CN117887849A (zh) | 一种子宫内膜良恶性病变的甲基化标志物及其应用 | |
| CN116814779A (zh) | 胃癌的生物标志物、核酸产品和试剂盒 |